Treatment of OC patients by niraparib was examined in clinical trials [29] and the EU and FDA approved olaparib to be used in combination with bevacizumab to treat advanced ovarian cancer; olaparib, similarly to niraparib, is a PARP inhibitor [30,31]. The gene discussed is PARP1; the disease is ovarian carcinoma.